Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
SkinJect
AddedFeb 16, 2024
UpdatedJun 18, 2026
SkinJect

SkinJect

Seed

SkinJect: Innovating non-melanoma skin cancer treatment through novel drug delivery systems.

HQ
Pittsburgh, PA, US
Founded
2015
Overview
Compare
Fundraising
Employees
Website

Founded with the mission to revolutionize dermatological treatments, SkinJect focuses on developing innovative drug delivery systems specifically for non-melanoma skin cancers, such as basal and squamous cell carcinoma. Their primary product, the SkinJect Patch, offers a simple and effective regimen to address these prevalent skin cancers, which affect a significant portion of the aging population. By targeting an unmet clinical need, SkinJect aims to improve patient outcomes and streamline treatment processes in dermatology.

SkinJect has garnered attention through its collaborations with academic institutions and industry experts. The company has achieved significant milestones in clinical trials, demonstrating the efficacy and safety of its patch technology. With backing from notable investors and a dedicated management team, SkinJect is poised to make a substantial impact on the treatment landscape for non-melanoma skin cancers, offering a less invasive and more accessible option for patients worldwide.

SkinJect - Similar Companies

VeraDermics logo

VeraDermics

veradermics.com

Skinvisible logo

Skinvisible

skinvisible.com

TheraJect logo

TheraJect

SkinCure Oncology logo

SkinCure Oncology

PellePharm logo

PellePharm

pellepharm.com

Strata Skin Sciences logo

Strata Skin Sciences

Avro Life Science logo

Avro Life Science

Enable Injections logo

Enable Injections

DermBiont logo

DermBiont

dermbiont.com

Dermamedics logo

Dermamedics

dermamedics.com

Microdermis logo

Microdermis

CureSkin logo

CureSkin

cureskin.com

Distinct Dermatology logo

Distinct Dermatology

Dermaliq Therapeutics logo

Dermaliq Therapeutics

dermaliq.com

DermaSensor logo

DermaSensor

dermasensor.com

SkinJect - Quick Facts

Who are SkinJect's competitors?

Companies similar to SkinJect include VeraDermics, Skinvisible, TheraJect and SkinCure Oncology.

When was SkinJect founded?

SkinJect was founded in 2015.

Where is SkinJect's headquarters located?

SkinJect's headquarters is located in Pittsburgh, PA, US.

When was SkinJect's last funding round?

SkinJect's most recent funding round was for $2.5M (USD) in May 2019.

How much has SkinJect raised to-date?

As of May 30, 2019, SkinJect has raised a total of $3M (USD).

How many employees does SkinJect have?

SkinJect has 11 employees as of Feb 5, 2024.

SkinJect - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
  • HealthTech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Drug Delivery
Tags
  • Healthcare
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
Show 11 more industry codes
NAICS
  • 456000Health and Personal Care Retailers
  • 450000Retail Trade
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
  • 456100Health and Personal Care Retailers
  • 456110Pharmacies and Drug Retailers
SIC
  • 5900Miscellaneous Retail
  • 8000Health Services
  • 5910Drug Stores And Proprietary Stores
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified